Fig. 1From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinomaComparison of survival outcomes between patients treated with sorafenib mono-therapy (sorafenib group) and those treated with transarterial chemoembolization plus sorafenib combination therapy (TACEÂ +Â sorafenib group). a Overall survival (OS, months). b Progression-free survival (PFS, months)Back to article page